The addition of angiotensin receptor blockers to angiotens-inconverting enzyme inhibitors—What has time told us?
- Mary Rose Fabi
- , John R. TeerlinkAffiliated withSan Francisco VA Medical Center
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The neurohormonal hypothesis for the pathogenesis of heart failure found an early champion in the angiotensinconverting enzyme (ACE) inhibitors. More recently, the β-blockers and aldosterone receptor antagonists have provided significant support by demonstrating marked additive clinical benefit. Within this context, angiotensin receptor blockers (ARBs) were specifically designed to antagonize one of the most potent contributors to the development and progression of heart failure, angiotensin. This review discusses the recent evidence for the addition of ARBs to standard therapy with ACE inhibitors and suggests how this evidence may be used to care for patients.
- The addition of angiotensin receptor blockers to angiotens-inconverting enzyme inhibitors—What has time told us?
Current Heart Failure Reports
Volume 2, Issue 2 , pp 59-64
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Industry Sectors